Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

XOMA

XOMA Royalty (XOMA)

XOMA Royalty Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XOMA
DateTimeSourceHeadlineSymbolCompany
02/04/20257:30AMGlobeNewswire Inc.XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:XOMAXOMA Royalty Corporation
12/19/20247:30AMGlobeNewswire Inc.XOMA Royalty Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
12/02/20247:30AMGlobeNewswire Inc.XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its PortfolioNASDAQ:XOMAXOMA Royalty Corporation
11/07/20247:30AMGlobeNewswire Inc.XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Royalty Corporation
10/22/20248:00AMGlobeNewswire Inc.XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist BioscienceNASDAQ:XOMAXOMA Royalty Corporation
09/23/20246:30AMGlobeNewswire Inc.Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)NASDAQ:XOMAXOMA Royalty Corporation
09/23/20245:30AMGlobeNewswire Inc.XOMA Royalty Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
09/04/20247:30AMGlobeNewswire Inc.XOMA Royalty to Present at Upcoming Investor Conferences in SeptemberNASDAQ:XOMAXOMA Royalty Corporation
08/13/20247:30AMGlobeNewswire Inc.XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Royalty Corporation
06/20/20247:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
06/12/20247:30AMGlobeNewswire Inc.XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review VoucherNASDAQ:XOMAXOMA Royalty Corporation
05/14/20247:30AMGlobeNewswire Inc.XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQNASDAQ:XOMAXOMA Royalty Corporation
05/09/20247:30AMGlobeNewswire Inc.XOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesNASDAQ:XOMAXOMA Royalty Corporation
04/30/20247:30AMGlobeNewswire Inc.XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%NASDAQ:XOMAXOMA Royalty Corporation
04/25/20247:30AMGlobeNewswire Inc.XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)NASDAQ:XOMAXOMA Royalty Corporation
04/24/20249:00AMPR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:XOMAXOMA Royalty Corporation
04/03/20249:00AMGlobeNewswire Inc.XOMA Corporation Announces Closing of Tender OfferNASDAQ:XOMAXOMA Royalty Corporation
03/21/20247:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
03/19/20244:05PMGlobeNewswire Inc.XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.NASDAQ:XOMAXOMA Royalty Corporation
03/08/20247:30AMGlobeNewswire Inc.XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Royalty Corporation
02/28/20247:30AMGlobeNewswire Inc.XOMA to Present at Upcoming Investor Conferences in MarchNASDAQ:XOMAXOMA Royalty Corporation
02/16/20248:00AMGlobeNewswire Inc.XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value RightNASDAQ:XOMAXOMA Royalty Corporation
01/18/20248:30AMGlobeNewswire Inc.XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® AcquisitionNASDAQ:XOMAXOMA Royalty Corporation
01/11/20244:50PMDow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:XOMAXOMA Royalty Corporation
01/11/20244:05PMGlobeNewswire Inc.FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxNASDAQ:XOMAXOMA Royalty Corporation
01/08/20247:30AMGlobeNewswire Inc.XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of DirectorsNASDAQ:XOMAXOMA Royalty Corporation
01/02/20247:30AMGlobeNewswire Inc.XOMA Announces Stock Repurchase Program of up to $50 MillionNASDAQ:XOMAXOMA Royalty Corporation
12/20/20237:30AMGlobeNewswire Inc.XOMA Declares Quarterly Preferred Stock DividendsNASDAQ:XOMAXOMA Royalty Corporation
12/19/20237:30AMGlobeNewswire Inc.XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesNASDAQ:XOMAXOMA Royalty Corporation
11/07/20237:30AMGlobeNewswire Inc.XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueNASDAQ:XOMAXOMA Royalty Corporation
 Showing the most relevant articles for your search:NASDAQ:XOMA